Teva Pharmaceutical Industries (TEVA) Short term Debt (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Short term Debt for 18 consecutive years, with $2.6 billion the latest figure, recorded in Q1 2026.

• Quarterly Short term Debt rose 520.43% year-over-year to $2.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 billion (up 520.43% YoY) and the FY2025 annual result came in at $1.8 billion, up 2.19% from the prior year.
• Short term Debt grew to $2.6 billion in Q1 2026 per TEVA's latest filing, from $1.8 billion in the prior quarter.
• Over the last five years, Short term Debt for TEVA reached as high as $3.1 billion in Q1 2024 and fell as low as $24.0 million in Q3 2025.
• A 5-year average of $1.7 billion and a median of $1.8 billion in 2025 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2025 — Short term Debt sank 99.07% — and 2026, when it jumped 520.43%.
• Year by year, Short term Debt stood at $2.1 billion in 2022, then decreased by 20.72% to $1.7 billion in 2023, then gained by 6.52% to $1.8 billion in 2024, then increased by 2.19% to $1.8 billion in 2025, then soared by 43.52% to $2.6 billion in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $2.6 billion, $1.8 billion, and $24.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.